Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Larson

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
Journal of Toxicology and Environmental Health. Part A|November 22, 2000
Myeloid leukemia after cytotoxic therapy and other hematotoxinsR A Larson
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|October 13, 2000
Patients' willingness to pay for pharmaceutical careR A Larson
Leukemia|April 1, 1996
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndromeR A Larson
Journal of Chemical Ecology|December 6, 2013
Insect defenses against phototoxic plant chemicalsR A Larson
Annals of Internal Medicine|July 1, 1985
Management of myelodysplastic syndromesR A Larson
Leukemia|March 21, 2003
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?R A Larson
Seminars in Hematology|July 28, 2001
Current use and future development of gemtuzumab ozogamicinR A Larson
Hematology/Oncology Clinics of North America|January 9, 2001
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group BR A Larson
Leukemia|May 23, 2001
New agents for induction and postremission therapy of acute myeloid leukemiaR A Larson
Annals of Hematology|May 6, 2004
The U.S. trials in adult acute lymphoblastic leukemiaR A Larson
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
Journal of Toxicology and Environmental Health. Part A|November 22, 2000
Myeloid leukemia after cytotoxic therapy and other hematotoxinsR A Larson
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|October 13, 2000
Patients' willingness to pay for pharmaceutical careR A Larson
Leukemia|April 1, 1996
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndromeR A Larson
Journal of Chemical Ecology|December 6, 2013
Insect defenses against phototoxic plant chemicalsR A Larson
Annals of Internal Medicine|July 1, 1985
Management of myelodysplastic syndromesR A Larson
Leukemia|March 21, 2003
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?R A Larson
Seminars in Hematology|July 28, 2001
Current use and future development of gemtuzumab ozogamicinR A Larson
Hematology/Oncology Clinics of North America|January 9, 2001
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group BR A Larson
Leukemia|May 23, 2001
New agents for induction and postremission therapy of acute myeloid leukemiaR A Larson
Annals of Hematology|May 6, 2004
The U.S. trials in adult acute lymphoblastic leukemiaR A Larson
Pageof 21